These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 11336056)

  • 21. Non-steroidal anti-inflammatory drug gastropathy: clinical results with H2 antagonists and proton pump inhibitors.
    Lazzaroni M; Bianchi Porro G
    Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S73-8. PubMed ID: 10379473
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs.
    Pilotto A; Franceschi M; Leandro G; Paris F; Cascavilla L; Longo MG; Niro V; Andriulli A; Scarcelli C; Di Mario F
    Aliment Pharmacol Ther; 2004 Nov; 20(10):1091-7. PubMed ID: 15569111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does famotidine have similar efficacy to misoprostol in the treatment of non-steroidal anti-inflammatory drug-induced gastropathy?
    Wu CS; Wang SH; Chen PC; Wu VC
    Int J Clin Pract; 1998 Oct; 52(7):472-4. PubMed ID: 10622088
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs.
    Castellsague J; Holick CN; Hoffman CC; Gimeno V; Stang MR; Perez-Gutthann S
    Pharmacotherapy; 2009 Dec; 29(12):1397-407. PubMed ID: 19947799
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.
    Laine L; Connors LG; Reicin A; Hawkey CJ; Burgos-Vargas R; Schnitzer TJ; Yu Q; Bombardier C
    Gastroenterology; 2003 Feb; 124(2):288-92. PubMed ID: 12557133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. A meta-analysis of randomized controlled clinical trials.
    Koch M; Dezi A; Ferrario F; Capurso I
    Arch Intern Med; 1996 Nov; 156(20):2321-32. PubMed ID: 8911239
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Misoprostol and NSAID ulcers.
    Isaacs P
    Am J Gastroenterol; 1996 Feb; 91(2):187-8. PubMed ID: 8607480
    [No Abstract]   [Full Text] [Related]  

  • 28. Rational use of anti-ulcer drugs to prevent serious gastroduodenal adverse effects associated with NSAIDS.
    Prescrire Int; 2011 Sep; 20(119):219. PubMed ID: 21954520
    [No Abstract]   [Full Text] [Related]  

  • 29. Prevention of NSAID-induced GI mucosal injury.
    Gerritz S; Newton WP
    J Fam Pract; 1997 Feb; 44(2):130-1. PubMed ID: 9040509
    [No Abstract]   [Full Text] [Related]  

  • 30. Double-blind, double-dummy endoscopic comparison of the mucosal protective effects of misoprostol versus ranitidine on naproxen-induced mucosal injury to the stomach and duodenum in rheumatic patients.
    Bianchi Porro G; Lazzaroni M; Petrillo M
    Am J Gastroenterol; 1997 Apr; 92(4):663-7. PubMed ID: 9128319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A clinical approach to management of patients with non-steroidal anti-inflammatory gastropathy.
    Yeomans ND
    Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S89-92. PubMed ID: 10379475
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Prevention and treatment of non-steroidal anti-inflammatory drug gastroenteropathy].
    Lanas A
    Rev Gastroenterol Mex; 2004; 69(4):251-60. PubMed ID: 15765979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs.
    Ray WA; Chung CP; Stein CM; Smalley WE; Hall K; Arbogast PG; Griffin MR
    Gastroenterology; 2007 Sep; 133(3):790-8. PubMed ID: 17854591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Misoprostol and NSAID.
    Weinstein WM
    J Clin Gastroenterol; 1991 Feb; 13(1):117. PubMed ID: 1901074
    [No Abstract]   [Full Text] [Related]  

  • 35. [Guidelines for good practice: anti-ulcer agents, indications in the adult. French Agency for Health Safety of Health Products].
    Therapie; 1999; 54(5):509-17. PubMed ID: 10667082
    [No Abstract]   [Full Text] [Related]  

  • 36. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
    Weir MR; Sperling RS; Reicin A; Gertz BJ
    Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tolerability of rofecoxib versus naproxen.
    Rusche JM
    Ann Intern Med; 2004 Jun; 140(12):1059; author reply 1060. PubMed ID: 15197028
    [No Abstract]   [Full Text] [Related]  

  • 38. Tolerability of rofecoxib versus naproxen.
    Jenkinson ML
    Ann Intern Med; 2004 Jun; 140(12):1059-60; author reply 1060. PubMed ID: 15197027
    [No Abstract]   [Full Text] [Related]  

  • 39. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
    Wolfe F; Anderson J; Burke TA; Arguelles LM; Pettitt D
    J Rheumatol; 2002 Mar; 29(3):467-73. PubMed ID: 11908558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tolerability of rofecoxib versus naproxen.
    Hanauer LB
    Ann Intern Med; 2004 Jun; 140(12):1059; author reply 1060. PubMed ID: 15197026
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.